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Background: The clinical utility of ankle-brachial index (ABI) is not clear in subjects with less severe or calcified vessel. Therefore, 
we investigated the usefulness of color Doppler ultrasonography for diagnosing peripheral artery disease (PAD) in type 2 diabetes 
mellitus (T2DM) subjects. 
Methods: We analyzed 324 T2DM patients who concurrently underwent ABI and carotid intima-media thickness (CIMT) mea-
surements and color Doppler ultrasonography from 2003 to 2006. The degree of stenosis in patients with PAD was determined 
according to Jager’s criteria, and PAD was defined as grade III (50% to 99% stenosis) or IV stenosis (100% stenosis) by color Dop-
pler ultrasonography. Logistic regression analysis and receiver operating characteristic curve analysis were performed to evaluate 
the risk factors for PAD in patients with ABI 0.91 to 1.40.
Results: Among the 324 patients, 77 (23.8%) had ABI 0.91 to 1.40 but were diagnosed with PAD. Color Doppler ultrasonography 
demonstrated that suprapopliteal arterial stenosis, bilateral lesions, and multivessel involvement were less common in PAD pa-
tients with ABI 0.91 to 1.40 than in those with ABI ≤0.90. A multivariate logistic regression analysis demonstrated that older age, 
current smoking status, presence of leg symptoms, and high CIMT were significantly associated with the presence of PAD in pa-
tients with ABI 0.91 to 1.40 after adjusting for conventional risk factors. CIMT showed significant power in predicting the pres-
ence of PAD in patients with ABI 0.91 to 1.40.
Conclusion: Color Doppler ultrasonography is a useful tool for the detection of PAD in T2DM patients with ABI 0.91 to 1.40 but 
a high CIMT.
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INTRODUCTION 
Peripheral artery disease (PAD) is a condition characterized by 
atherosclerotic occlusive disease of the lower extremities. The 
prevalence of PAD is increased with advanced age, cigarette 
smoking, diabetes mellitus (DM), dyslipidemia, and hyperten-
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sion [1-3]. PAD is a major risk factor for coronary and cerebro-
vascular events, including myocardial infarction, stroke, and 
death, secondary to systemic atherothrombosis [3,4]. PAD is 
rarely an isolated condition, but rather a manifestation of sys-
temic atherosclerosis in other vascular beds, including the cor-
onary and carotid arteries in patients with DM [3,5]. PAD is 3- 
to 4-fold higher in incidence and more extensive but less 
symptomatic in patients with DM compared with normal sub-
jects [1,6]. Notably, because the rate of limb amputation due to 
PAD is significantly higher in patients with DM [7], early de-
tection of asymptomatic PAD in patients with DM has impor-
tant implications in clinical practice.
Although non-invasive and simple diagnostic tests are read-
ily available, PAD remains significantly underestimated and 
untreated [8], mostly because of the paucity of symptoms and 
underutilization of screening tools. The American Diabetes 
Association Consensus Statement recommends that a screen-
ing ankle-brachial index (ABI) should be performed in diabe-
tes patients with symptoms or signs of PAD [9]. However, the 
accuracy of the ABI is controversial when used to evaluate cal-
cified and poorly compressible vessels in elderly patients with 
medial sclerosis. The ABI may also be falsely negative in symp-
tomatic patients with moderate aortoiliac stenosis or extensive 
collaterals [10]. Therefore, various imaging tools, such as color 
Doppler ultrasonography, magnetic resonance angiography 
(MRA), and computed tomography angiography (CTA) have 
been used to diagnose suspicious PAD despite a normal ABI 
[11]. Although all of these tests are non-invasive, color Dop-
pler ultrasonography provides renal protection because con-
trast dye is not used, compared with MRA or CTA. A previous 
study also reported that hand-held Doppler has the greatest di-
agnostic accuracy in patients with PAD, while clinical findings 
including claudication, femoral bruit, and pulse abnormalities 
are insufficient to diagnose PAD [12].
Carotid intima-media thickness (CIMT), which is easily as-
sessed by B-mode ultrasound, is an indicator of generalized 
atherosclerosis and a potentially effective tool to predict vascu-
lar complications in patients with DM [13]. In fact, an in-
creased CIMT is related to a higher risk of PAD detected by 
ABI and claudication [14,15].
This study assessed the utility of color Doppler ultrasonog-
raphy to detect PAD in type 2 diabetes mellitus (T2DM) pa-
tients with ABI 0.91 to 1.40. In addition, we investigated the 
usefulness of CIMT in predicting the presence of PAD in DM 
patients with ABI 0.91 to 1.40. 
METHODS
Subjects
This was a single center, retrospective study performed at Huh’s 
Diabetes Center in Seoul, Republic of Korea. Among the pa-
tients who visited this clinic from January 2003 to December 
2006, we analyzed 324 T2DM patients over 50 years of age, and 
their vascular stenosis was concurrently evaluated by the ABI, 
color Doppler ultrasonography, and CIMT. Subjects who had a 
previous history of ketoacidosis, serum fasting C-peptide level 
≤0.5 ng/mL, history of cardiovascular disease (CVD) includ-
ing stroke, myocardial infarction, any coronary revasculariza-
tion or surgery due to chest pain and hospitalization due to 
heart failure, history of PAD, or a diagnosis of an orthopedic 
disease in the lumbar spine were excluded. All subjects were 
categorized into three groups according to their leg symptoms: 
the asymptomatic, typical, and atypical symptomatic groups. 
The typical symptomatic group included patients with symp-
tomatic claudication, resting pain, and necrosis or gangrene, 
which are compatible with typical symptoms in the Fontaine 
staging system [16]. The atypical symptomatic group included 
patients with vague pain, which was difficult to distinguish 
from symptoms of peripheral neuropathy. This study was ap-
proved by the Institutional Review Board of Yonsei University 
(IRB No. 4-2017-0288). Due to the retrospective nature of this 
study, the requirement for written informed consent was waived. 
Measurement of anthropometric and biochemical 
parameters
Height (cm) and body weight (kg) were measured to the near-
est 0.1 cm and 0.1 kg, respectively, in barefoot subjects wearing 
light clothing. Body mass index (BMI) was calculated as 
weight divided by height squared (kg/m2). Waist circumfer-
ence was measured to the nearest 0.1 cm at the narrowest point 
between the lower limit of the ribcage and the iliac crest. Blood 
pressure (BP) was recorded using a mercury sphygmomanom-
eter on the right arm with the subject in the sitting position. 
Two readings were taken 5 minutes apart, and the mean value 
was used. All patients were asked about their smoking history 
and were classified as never-smokers, ex-smokers, or current 
smokers using a structured questionnaire. Subjects were also 
asked to refrain from smoking for 24 hours and from consum-
ing alcohol for 7 days before the blood sampling.
After a 14-hour overnight fast, venous blood samples were 
drawn from the antecubital vein between 7:00 AM and 9:00 
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AM. Plasma was separated immediately by centrifugation 
(2,000 rpm, 20 minutes, at 4°C), and biochemical measure-
ments were determined immediately. Fasting plasma concen-
trations of glucose, total cholesterol, triglycerides, and high 
density lipoprotein cholesterol and low density lipoprotein 
cholesterol were measured enzymatically using the Hitachi 747 
chemical analyzer (Hitachi, Tokyo, Japan). The glycosylated 
hemoglobin (HbA1c) value was determined using a high-per-
formance liquid chromatography method (Varient II; Green-
cross, Seoul, Korea). Fasting and 2-hour postprandial C-pep-
tide levels were measured by double-antibody radioimmuno-
assay (DiaSorin, Stillwater, MN, USA). 
Ankle-brachial index 
A non-invasive screening device (VP-1000; Colin Medical 
Technology Corp., Komaki, Japan) was used to measure the 
ABI. All patients were allowed to rest for at least 5 minutes be-
fore the measurements. The American College of Cardiology/
American Heart Association (ACC/AHA) guidelines [17] rec-
ommend selecting the higher of the two arm pressures (bra-
chial) and the higher of the two ankle pressures (anterior tibi-
al/dorsalis pedis or posterior tibial) to calculate the ABI. The 
lower of the two ABI values was used for the analysis. Accord-
ing to the ACC/AHA recommendations the ABI value was 
classified as follows: normal, 1.00 to 1.40; borderline, 0.91 to 
0.99; abnormal, ≤0.90 (mild, 0.70 to 0.90; moderate, 0.40 to 
0.69; severe, <0.40); and poorly compressible >1.40 [17].
Peripheral color Doppler ultrasonography
All Doppler studies were performed by a single radiologist us-
ing color Doppler ultrasonography (Logic 7; General Electron-
ics, Milwaukee, WI, USA). Information on the presence and 
grade of stenosis, post-stenotic turbulence, peak systolic veloc-
ity, end diastolic velocity, and the presence of collaterals and 
their flow characteristics were assessed on color Doppler imag-
ing. The degree of stenosis was graded according to Jager’s cri-
teria. Normal, triphasic waveform with thin spectral band. 
Grade I, 1% to 19% stenosis: normal triphasic flow with nor-
mal peak systolic velocity with spectral broadening. Grade II, 
20% to 49% stenosis: triphasic waveform with an increase in 
peak systolic velocity ≥30% with respect to the proximal re-
cording site. Marked spectral broadening. Grade III, 50% to 
99% stenosis: monophasic waveform with an increase in peak 
systolic velocity ≥100% and marked spectral broadening. Dis-
tal waveform is abnormal. Grade IV, 100% stenosis: no forward 
flow detected with altered flow patterns both proximal and 
distal to the stenosis [18]. Grade III and IV stenoses were de-
fined as PAD in this study. 
Carotid intima-media thickness
Both carotid arteries were scanned by a single experienced ex-
aminer using high-resolution real-time B mode ultrasonogra-
phy with a 10 MHZ probe (LOGIQ 7; General Electronics), as 
previously described [19]. The CIMT was defined as the dis-
tance between the lumen-intima and media-adventitia inter-
faces [20]. CIMT was measured at three points on the far wall 
in sections (1 cm long) of the common carotid artery in the 
proximity of the carotid bulb. The mean of six measurements 
from the right and left carotid arteries was used as the mean 
CIMT [21].
Statistical analysis 
Normally distributed data are expressed as mean±standard 
deviation, and categorical variables are expressed as percentag-
es. One-way analysis of variance or Student t-test was used to 
compare continuous variables, and the chi-square test was 
used to compare categorical variables. Logistic regression anal-
yses were performed using the enter method to identify the 
risk factors for PAD in patients with ABI 0.91 to 1.40. Receiver 
operating characteristic (ROC) analysis was performed to as-
sess the utility of CIMT in predicting PAD in symptomatic and 
asymptomatic patients with ABI 0.91 to 1.40. All statistical 
tests were two-sided, and analyses were executed using SPSS 
for Windows version 23.0 (IBM Co., Armonk, NY, USA). A P 
value <0.05 was considered significant.
RESULTS 
Baseline clinical characteristics 
A total of 324 patients were analyzed in this study (male: 
female=192:132). The mean age of all subjects was 62.5±7.3 
years, and BMI was 24.5±2.9 kg/m2. Mean DM duration was 
11.4±7.3 years, and the mean HbA1c was 8.4%±1.8%.
Table 1 shows the clinical characteristics of the subjects with 
and without PAD. The PAD group was older, more likely male, 
and lower in BMI. The PAD group had more current smokers 
and a longer duration of DM. Other metabolic parameters, in-
cluding fasting plasma glucose levels, lipid levels, and waist cir-
cumference, did not differ between the groups. Systolic and di-
astolic BP was higher, and leg symptoms were more common, 
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in the PAD group. The proportions of abnormal or borderline 
ABI were higher in PAD group, compared with non-PAD 
group. The mean CIMT was also significantly higher in the 
PAD group, compared with non-PAD group. 
Comparison of anatomical characteristics between the 
patients with ABI 0.91 to 1.40 vs. ≤0.90 among patients 
with PAD 
The clinical presentation of PAD according to the ABI and col-
or Doppler ultrasonography results is detailed in Fig. 1. Among 
the 324 patients, only 18 (5.6%) had an abnormally low ABI 
(≤0.90) and the other 306 (94.4%) had ABI 0.91 to 1.40. How-
ever, color Doppler ultrasonography demonstrated that 93 
(28.7%) had PAD. Among the 93 patients diagnosed with PAD 
by Doppler ultrasonography, only 16 (17.2%) had an abnor-
mally low ABI, and 77 (82.8%) had ABI 0.91 to 1.40. Among 
the 306 patients with ABI 0.91 to 1.40, 34 (11.1%) had grade III 
(50% to 99% stenosis) lesions, and 43 (14.1%) had grade IV 
(100% stenosis) lesions on color Doppler ultrasonography 
(Fig. 2). These results suggest that the ABI has the potential to 
underestimate the presence of PAD.
Next, we compared the characteristics of the stenotic lesions 
Table 1. Clinical characteristics of type 2 diabetes mellitus patients with and without PAD diagnosed by color Doppler ultraso-
nography (n=324)
Characteristic Total PAD (–) PAD (+) P value
No. of patients 324 231 (71.3) 93 (28.7)
Age, yr 62.5±7.3 61.2±6.9 65.8±7.2 <0.001
Male sex 192 (59.3) 129 (55.8) 63 (67.7) 0.049
BMI, kg/m2 24.5±2.9 24.7±2.9 23.9±2.7 0.018
Waist circumference, cm 84.9±7.6 85.1±7.9 84.5±6.9 0.562
Systolic BP, mm Hg 141.4±19.3 139.9±18.4 145.1±21.1 0.028
Diastolic BP, mm Hg 87.1±11.0 85.0±12.2 87.9±10.4 0.031
DM duration, yr 11.4±7.3 10.5±6.6 13.5±8.4 0.001
Current smoker 52 (16.0) 31 (13.4) 21 (22.6) 0.002
Use of insulin 59 (18.2) 37 (16.0) 22 (23.7) 0.107
Use of statins 50 (15.4) 33 (14.3) 17 (18.3) 0.368
Use of anti-hypertensive drugs 110 (34.0) 76 (32.9) 34 (36.6) 0.529
HbA1c, % 8.4±1.8 8.4±1.8 8.5±1.7 0.741
Fasting glucose, mg/dL 163.3±57.0 164.1±56.1 161.4±59.6 0.701
Total cholesterol, mg/dL 193.4±41.5 193.1±42.6 194.2±38.7 0.831
Triglycerides, mg/dL 148.5±95.1 153.6±107.0 135.8±53.3 0.131
HDL-C, mg/dL 49.6±14.5 50.3±14.7 48.0±13.8 0.183
LDL-C, mg/dL 113.5±35.5 111.4±36.5 118.9±32.5 0.103
Leg symptoms (yes)
   Typical 43 (13.3) 6 (2.6) 37 (39.8) <0.001
   Atypical 31 (9.6) 19 (8.2) 12 (12.9) 0.006
ABI 
   ≤0.90 (abnormal) 18 (5.6) 2 (11.1) 16 (88.9) <0.001
   0.91–0.99 (borderline) 15 (4.6) 7 (46.7) 8 (53.3) 0.010
Mean CIMT, mm 0.94±0.23 0.90±0.19 1.03±0.27 <0.001
Values are presented as number (%) or mean±standard deviation. 
PAD, peripheral artery disease; BMI, body mass index; BP, blood pressure; DM, diabetes mellitus; HbA1c, glycosylated hemoglobin; HDL-C, 
high density lipoprotein cholesterol; LDL-C, low density lipoprotein cholesterol; ABI, ankle-brachial index; CIMT, carotid intima-media thick-
ness. 
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between ABI 0.91 to 1.40 and ABI ≤0.90 among the patients 
with PAD (Table 2). Multiple stenotic lesions were less frequent 
in ABI 0.91 to 1.40 group than in ABI ≤0.90 group. Although 
stenotic lesions occurred most frequently in the infrapopliteal 
arteries, such as the anterior and posterior tibial arteries, in 
both groups, stenosis of the common femoral (14.3% vs. 
37.5%, P=0.029) or superficial femoral (22.1% vs. 32.0%, 
P=0.022) arteries was less frequent in ABI 0.91 to 1.40 group 
than in ABI ≤0.90 group. Bilateral stenosis was also less com-
mon in ABI 0.91 to 1.40 group than in ABI ≤0.90 group 
(64.9% vs. 93.8%, P=0.022). Collectively, multiple, proximal, 
and bilateral arterial stenoses were less common in ABI 0.91 to 
1.40 group than in ABI ≤0.90 group, suggesting that the ABI 
alone potentially underestimates PAD if the stenotic lesions are 
less extensive, distal, or unilateral.
Comparison of clinical characteristics between the patients 
with ABI 0.91 to 1.40 vs. ≤0.90 among the patients with 
PAD 
We compared the clinical characteristics between patients with 
ABI 0.91 to 1.40 versus ≤0.90 among patients with PAD (Table 
3). No significant differences in age, sex, or BMI were observed 
between the groups. In addition, no significant differences in 
BP, HbA1c, lipid profile, or smoking history were observed be-
tween the groups. However, ABI ≤0.90 group had a longer du-
ration of DM, more frequent insulin use, and more frequent 
leg symptoms compared with those in ABI 0.91 to 1.40 group. 
Although the mean CIMT was significantly higher in patients 
324 Subjects
306 ABI 0.91–1.40
229 Less than Grade II stenosis
93 PAD
16 Grade III & IV stenosis
18 ABI ≤0.90
77 Grade III & IV stenosis 2 Less than Grade II stenosis
Fig. 1. Flow chart presenting the study subjects. ABI, ankle-brachial index; PAD, peripheral artery disease.
Fig. 2. Degree of stenosis on color Doppler ultrasonography in patients with ankle-brachial index 0.91 to 1.40 (n=306).  Grade III 
and IV stenoses were defined as peripheral artery disease and expressed with gray bars.
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with PAD than in those without PAD (1.03±0.27 mm vs. 
0.90±0.19 mm, P<0.001) (Table 1), no difference in CIMT 
was observed between the patients with ABI 0.91 to 1.40 and 
≤0.90 among the patients with PAD (Table 3). 
Risk factors associated with PAD among the patients with 
ABI 0.91 to 1.40 
The ABI is a more accessible tool for screening PAD in the 
clinical setting than is color Doppler ultrasonography. Howev-
er, it has the potential to underestimate the presence of PAD, 
which may delay proper management. If we could find out the 
characteristics of the patients with PAD who had ABI 0.91 to 
1.40, further vascular evaluation could be recommended for 
them. Thus, we investigated the risk factors associated with the 
presence of PAD in the 306 patients with ABI 0.91 to 1.40. 
Univariate analysis demonstrated that older age, a longer dura-
tion of DM, current smoking status, leg symptoms, and a high-
er mean CIMT were associated with the presence of PAD in 
patients with ABI 0.91 to 1.40 (Table 4). In the multivariate 
analysis, we adjusted for age, sex, BMI, systolic BP, DM dura-
tion, current smoking status, HbA1c, total cholesterol, pres-
ence of leg symptoms, and mean CIMT (Table 4). The results 
demonstrated that age per 10 years (odds ratio [OR], 1.86; 95% 
confidence interval [CI], 1.18 to 2.93; P=0.008), current smok-
ing status (OR, 2.62; 95% CI, 1.10 to 6.21; P=0.029), leg symp-
toms (OR, 7.35; 95% CI; 3.71 to 14.57; P<0.001), and mean 
CIMT (OR, 4.73; 95% CI, 1.14 to 19.57; P=0.032) were signifi-
cantly associated with the presence of PAD in these patients 
(Table 4). After adjusting for age as a categorical variable in the 
multivariate analysis, age ≥70 years was significantly associat-
ed with a higher risk of PAD (OR, 3.08; 95% CI, 1.23 to 7.69; 
P=0.016) compared with age <60 years. There was no differ-
ence in the risk of PAD between the 60 to 69 and <60-year age 
groups (OR, 2.04; 95% CI, 0.97 to 4.30; P=0.061) (data not 
shown).
The cut-off CIMT value to predict the presence of PAD was 
Table 2. Comparison of anatomical characteristics of patients 
with ABI 0.91 to 1.40 vs. ABI ≤0.90 among the patients diag-
nosed with PAD by color Doppler ultrasonography (n=93)
Anatomical characteristic
ABI
0.91–1.40 ≤0.90 P value
No. of patients 77 (82.8) 16 (17.2)
No. of stenoses 2 (1–4) 4 (2–5) 0.005
Location of stenosis
   Common iliac artery 8 (10.4) 3 (18.8) 0.346
   Common femoral artery 11 (14.3) 6 (37.5) 0.029
   Superficial femoral artery 17 (22.1) 8 (32.0) 0.022
   Deep femoral artery 10 (13.0) 4 (25.0) 0.221
   Popliteal artery 11 (14.3) 5 (31.3) 0.102
   Anterior tibial artery 53 (68.8) 13 (81.3) 0.319
   Posterior tibial artery 42 (54.5) 10 (62.5) 0.560
Bilateral lesions 50 (64.9) 15 (93.8) 0.022
Values are presented as number (%) or median (interquartile range). 
ABI, ankle-brachial index; PAD, peripheral artery disease.
Table 3. Comparison of the clinical characteristics of patients 
with ABI 0.91 to 1.40 vs. ABI ≤0.90 among the patients diag-
nosed with PAD by color Doppler ultrasonography (n=93)
Variable
ABI
0.91–1.40 ≤0.90 P value
No. of patients 77 (82.8) 16 (17.2)
Age, yr 65.2±7.0 68.6±8.0 0.084
Male sex 51 (66.2) 12 (75.0) 0.495
BMI, kg/m2 24.0±2.7 23.1±2.5 0.204
Waist circumference, cm 84.9±7.2 82.9±4.8 0.324
Systolic BP, mm Hg 144.1±21.7 149.8±17.3 0.329
Diastolic BP, mmHg 81.1±11.1 85.8±12.3 0.163
DM duration, yr 12.4±8.0 18.9±8.5 0.004
Current smoker 18 (23.4) 3 (18.8) 0.687
Use of insulin 15 (19.5) 7 (43.8) 0.038
Use of statins 12 (15.6) 5 (31.3) 0.140
Use of anti-hypertensive 
drugs
27 (35.1) 7 (43.8) 0.512
HbA1c, % 8.4±1.6 9.1±1.9 0.099
Fasting glucose, mg/dL 156.3±53.9 185.8±79.6 0.071
Total cholesterol, mg/dL 193.6±40.2 196.7±31.6 0.776
Triglycerides, mg/dL 137.4±55.7 129.2±42.0 0.581
HDL-C, mg/dL 48.4±14.0 45.9±13.3 0.511
LDL-C, mg/dL 117.6±33.0 125.5±30.2 0.428
Leg symptoms 
(typical+atypical) 
37 (48.1) 12 (75.0) 0.044
Mean CIMT, mm 1.02±0.27 1.10±0.24 0.247
Values are presented as number (%) or mean±standard deviation. 
ABI, ankle-brachial index; PAD, peripheral artery disease; BMI, body 
mass index; BP, blood pressure; DM; diabetes mellitus; HbA1c, glyco-
sylated hemoglobin; HDL-C, high density lipoprotein cholesterol; 
LDL-C, low density lipoprotein cholesterol; CIMT, carotid intima-
media thickness. 
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0.92 mm, with a 62.3% sensitivity and 59.0% specificity. ROC 
analysis demonstrated that the area under the curve was 0.69 
(95% CI, 0.56 to 0.83; P=0.010) for the symptomatic patients 
(Fig. 3A) and 0.68 (95% CI, 0.61 to 0.76; P=0.001) for the as-
ymptomatic patients (Fig. 3B). Collectively, these results sug-
gest that older age (≥70 years), current smoking status, pres-
ence of leg symptoms, high mean CIMT (>0.92 mm) were 
factors associated with the presence of PAD, even in patients 
with ABI 0.91 to 1.40. 
DISCUSSION 
PAD is strongly associated with cardiovascular mortality and 
lower extremity amputation in patients with DM. The use of 
ABI is commonly recommended in screening for PAD in pa-
tients with DM. However, our study demonstrated that 25.2% 
of patients with DM and ABI 0.91 to 1.40 were diagnosed with 
PAD by color Doppler ultrasonography. Older age, current 
smoking status, presence of leg symptoms, and high CIMT 
were significantly associated with the presence of PAD in pa-
tients with ABI 0.91 to 1.40. 
The prevalence of PAD detected by the ABI was previously 
reported to be 20% in a population with DM [22], and reached 
29% in older diabetes patients over 50 years of age [23]. An 
Asian study (PAD-SEARCH) showed that the prevalence of 
PAD was 17.7%, but this rate varied (12% to 32%) depending 
on the region. The prevalence of PAD in Koreans over 50 years 
of age was 12% from the 1980s to the 1990s, which is lower 
compared with other regions [24]. The difference may be asso-
ciated with the heterogeneity of the study participants as well 
as the limitations of the ABI, which can underestimate the 
prevalence of PAD. Our results also demonstrate different 
Table 4. Risk factors associated with the presence of PAD in 306 patients with ABI 0.91 to 1.40
Variable
Univariate analysis Multivariate analysisa
OR (95% CI) P value OR (95% CI) P value
Age (per 10 yr) 2.23 (1.51–3.28) <0.001 1.86 (1.18–2.93) 0.008
Male sex 1.55 (0.90–2.66) 0.113 1.07 (0.53–2.21) 0.853
BMI, kg/m2 0.92 (0.84–1.01) 0.090 0.92 (0.82–1.03) 0.158
Waist circumference, cm 1.00 (0.96–1.03) 0.877
Systolic BP (per 10 mm Hg) 1.12 (0.98–1.28) 0.096 1.02 (0.99–1.06) 0.085
Diastolic BP (per 10 mm Hg) 0.84 (0.66–1.06) 0.145
DM duration, yr 1.04 (1.01–1.07) 0.042 1.02 (0.98–1.06) 0.402
Current smoker 1.95 (1.02–3.73) 0.044 2.62 (1.10–6.21) 0.029
Use of insulin (yes) 1.30 (0.67–2.53) 0.445
Use of statins (yes) 1.10 (0.54–2.25) 0.801
Use of anti-hypertensive drugs (yes) 1.09 (0.63–1.87) 0.763
HbA1c, % 0.98 (0.85–1.14) 0.807 0.89 (0.74–1.07) 0.222
Fasting glucose, mg/dL 1.00 (0.99–1.00) 0.303
Total cholesterol, mg/dL 1.00 (0.99–1.01) 0.932 1.00 (0.99–1.01) 0.783
Triglycerides, mg/dL 1.00 (0.99–1.00) 0.193
HDL-C, mg/dL 0.99 (0.97–1.01) 0.306
LDL-C, mg/dL 1.01 (0.99–1.01) 0.200
Leg symptoms (yes) 7.55 (4.10–13.89) <0.001 7.35 (3.71–14.57) <0.001
Mean CIMT, mm 10.46 (3.12–35.03) <0.001 4.73 (1.14–19.57) 0.032
PAD, peripheral artery disease; ABI, ankle-brachial index; OR, odds ratio; CI, confidence interval; BMI, body mass index; BP, blood pressure; 
DM, diabetes mellitus; HbA1c, glycosylated hemoglobin; HDL-C, high density lipoprotein cholesterol; LDL-C, low density lipoprotein choles-
terol; CIMT, carotid intima-media thickness. 
aMultivariate model was adjusted for age, sex, BMI, systolic BP, DM duration, current smoking status, HbA1c level, total cholesterol level, leg 
symptoms, and mean CIMT. 
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prevalence rates of PAD according to the detection method 
used (5.6% by ABI vs. 28.7% by color Doppler ultrasonogra-
phy).
Among subjects who have ABI 0.91 to 1.40 but are diag-
nosed with PAD, only 39.8% showed typical leg symptoms of 
PAD in this study. This result supports a previous study that 
the proportion of asymptomatic PAD is significantly higher 
among subjects with DM than among normal subjects [25]. 
Approximately 27% of patients with PAD demonstrate a pro-
gression of symptoms over a 5-year period, with limb loss oc-
curring in 4% [26]. Patients with DM and claudication show 
an overall 20% amputation risk and a 50% 5-year mortality 
rate [27]. Considering the impact of PAD on the mortality and 
morbidity of patients with DM, early diagnosis and proper 
management of PAD are important, even in asymptomatic pa-
tients. 
ABI value of 0.91 to 0.99 is defined as a borderline [17] and 
is known to be associated with an increased risk of PAD [28], 
endothelial dysfunction [29], and hard CVD events [30,31], 
compared with a normal ABI (1.00 to 1.40). Our study also 
showed that the proportion of borderline ABI was higher in 
PAD group compared with non-PAD group (10.4% vs. 3.1%, 
P=0.010) in Table 1. However, among 77 patients who have 
ABI 0.91 to 1.40 and PAD, only eight patients (53.3%) had a 
borderline ABI and the other 69 patients (23.7%) had a normal 
ABI. This results suggests that not only a borderline ABI but 
also a normal ABI cannot exclude the possibility of detecting 
PAD by color Doppler ultrasonography. Since the ABI has lim-
ited sensitivity and a large number of DM patients are asymp-
tomatic, we may consider the further vascular evaluation to 
detect PAD for not only for the symptomatic but also for the 
asymptomatic patients who have ABI 0.91 to 1.40 and known 
risk factors.
Color Doppler ultrasonography is a good vascular imaging 
technology because of its noninvasiveness, safety, and accuracy 
[32]. It visualizes vessels directly and provides data regarding 
anatomical localization, the degree of stenosis, and hemody-
namics. One study reported that color Doppler ultrasonogra-
phy has an 80% to 98% sensitivity and 89% to 99% specificity 
for diagnosis of PAD [33]. A previous study reported that the 
prevalence of PAD, as detected by color Doppler ultrasonogra-
phy, was 24% in patients with DM, male predominance, and a 
tendency for multisegmental and infrapopliteal artery involve-
ment [34].
CIMT measured by high-resolution ultrasonography is a 
good marker of generalized atherosclerosis [35,36]. CIMT was 
positively associated with the prevalence of PAD [37], and 
found to be an independent predictor of peripheral revascular-
ization [38]. Our study also reported that a high CIMT was 
significantly associated with the presence of PAD in patients 
with ABI 0.91 to 1.40, independent of leg symptoms or known 
risk factors such as age, sex, smoking, hypertension, and lipid 
levels. Thus, color Doppler ultrasonography may be useful for 
detecting PAD in patients with ABI 0.91 to 1.40 and a high 
Fig. 3. Receiver operating characteristic curves for carotid intima-media thickness (CIMT) for predicting peripheral artery dis-
ease (PAD) in 306 patients with ankle-brachial index 0.91 to 1.40. (A) The area under the curve for CIMT for predicting PAD in 
symptomatic type 2 diabetes mellitus (T2DM) patients (n=62). (B) The area under the curve (AUC) for CIMT for predicting 
PAD in asymptomatic T2DM patients (n=244). 
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CIMT, regardless of leg symptoms.
This study had several limitations that should be considered. 
First, the subjects may not be representative of the general 
population, because they were enrolled from a single diabetes 
center, and may have had asymptomatic CVD that was not ex-
cluded at the enrollment. Second, we could not specify ortho-
pedic diseases in the lumbar spine such as spinal stenosis, any 
spinal operation, or compression fracture due to lack of the 
data. Lastly, there were also lack of data on the use of anti-
platelet agents, changes in statin or anti-hypertensive medica-
tions, even though these factors may affect vascular function. 
However, the strength of this study is that we identified the 
utility of color Doppler ultrasonography in detecting PAD, es-
pecially in patients with a normal or borderline ABI. 
In conclusion, color Doppler ultrasonography could be use-
ful for the detection of PAD among patients with DM and a 
normal or borderline ABI. Color Doppler ultrasonography 
could be considered for not only symptomatic but also asymp-
tomatic patients who have ABI 0.91 to 1.40 and a high CIMT. 
CONFLICTS OF INTEREST 
No potential conflict of interest relevant to this article was re-
ported.
ACKNOWLEDGMENTS 
This work was supported by a grant from the Seoul R&BD Pro-
gram, Republic of Korea (10526). Kyu Yeon Hur is the recipient 
of grants from Samsung Medical Center (#CRP1500057).
REFERENCES
1.  Selvin E, Erlinger TP. Prevalence of and risk factors for periph-
eral arterial disease in the United States: results from the Na-
tional Health and Nutrition Examination Survey, 1999-2000. 
Circulation 2004;110:738-43.
2.  Eraso LH, Fukaya E, Mohler ER 3rd, Xie D, Sha D, Berger JS. 
Peripheral arterial disease, prevalence and cumulative risk fac-
tor profile analysis. Eur J Prev Cardiol 2014;21:704-11.
3.  Criqui MH, Aboyans V. Epidemiology of peripheral artery dis-
ease. Circ Res 2015;116:1509-26.
4.  Sigvant B, Hasvold P, Kragsterman B, Falkenberg M, Johansson 
S, Thuresson M, Nordanstig J. Cardiovascular outcomes in pa-
tients with peripheral arterial disease as an initial or subse-
quent manifestation of atherosclerotic disease: results from a 
Swedish nationwide study. J Vasc Surg 2017;66:507-14.
5.  Olin JW, Sealove BA. Peripheral artery disease: current insight 
into the disease and its diagnosis and management. Mayo Clin 
Proc 2010;85:678-92.
6.  Gregg EW, Sorlie P, Paulose-Ram R, Gu Q, Eberhardt MS, Wolz 
M, Burt V, Curtin L, Engelgau M, Geiss L; 1999-2000 national 
health and nutrition examination survey. Prevalence of lower-
extremity disease in the US adult population >=40 years of age 
with and without diabetes: 1999-2000 national health and nu-
trition examination survey. Diabetes Care 2004;27:1591-7.
7.  Shammas AN, Jeon-Slaughter H, Tsai S, Khalili H, Ali M, Xu H, 
Rodriguez G, Cawich I, Armstrong EJ, Brilakis ES, Banerjee S. 
Major limb outcomes following lower extremity endovascular 
revascularization in patients with and without diabetes melli-
tus. J Endovasc Ther 2017;24:376-82.
8.  Bhatt DL, Steg PG, Ohman EM, Hirsch AT, Ikeda Y, Mas JL, 
Goto S, Liau CS, Richard AJ, Rother J, Wilson PW; REACH 
Registry Investigators. International prevalence, recognition, 
and treatment of cardiovascular risk factors in outpatients with 
atherothrombosis. JAMA 2006;295:180-9.
9.  American Diabetes Association. 10. Microvascular complica-
tions and foot care: standards of medical care in diabetes-2018. 
Diabetes Care 2018;41(Suppl 1):S105-18.
10.  Dhaliwal G, Mukherjee D. Peripheral arterial disease: epidemi-
ology, natural history, diagnosis and treatment. Int J Angiol 
2007;16:36-44.
11.  American Diabetes Association. Peripheral arterial disease in 
people with diabetes. Diabetes Care 2003;26:3333-41.
12.  Khan NA, Rahim SA, Anand SS, Simel DL, Panju A. Does the 
clinical examination predict lower extremity peripheral arterial 
disease? JAMA 2006;295:536-46.
13.  Sibal L, Agarwal SC, Home PD. Carotid intima-media thick-
ness as a surrogate marker of cardiovascular disease in diabe-
tes. Diabetes Metab Syndr Obes 2011;4:23-34.
14.  Bots ML, Hofman A, Grobbee DE. Common carotid intima-
media thickness and lower extremity arterial atherosclerosis. 
The Rotterdam Study. Arterioscler Thromb 1994;14:1885-91.
15.  Poredos P, Golob M, Jensterle M. Interrelationship between 
peripheral arterial occlusive disease, carotid atherosclerosis 
and flow mediated dilation of the brachial artery. Int Angiol 
2003;22:83-7.
16.  Borssen B, Bergenheim T, Lithner F. The epidemiology of foot 
lesions in diabetic patients aged 15-50 years. Diabet Med 
1990;7:438-44.
Hur KY, et al.
72 Diabetes Metab J 2018;42:63-73 http://e-dmj.org
17.  Gerhard-Herman MD, Gornik HL, Barrett C, Barshes NR, 
Corriere MA, Drachman DE, Fleisher LA, Fowkes FG, Ham-
burg NM, Kinlay S, Lookstein R, Misra S, Mureebe L, Olin JW, 
Patel RA, Regensteiner JG, Schanzer A, Shishehbor MH, Stew-
art KJ, Treat-Jacobson D, Walsh ME. 2016 AHA/ACC guide-
line on the management of patients with lower extremity pe-
ripheral artery disease: executive summary. A report of the 
American College of Cardiology/American Heart Association 
Task Force on Clinical Practice Guidelines. Circulation 
2017;135:e686-725.
18.  Jager KA, Phillips DJ, Martin RL, Hanson C, Roederer GO, 
Langlois YE, Ricketts HJ, Strandness DE Jr. Noninvasive map-
ping of lower limb arterial lesions. Ultrasound Med Biol 1985; 
11:515-21.
19.  Jun JE, Choi YJ, Lee YH, Kim DJ, Park SW, Huh BW, Lee EJ, Jee 
SH, Hur KY, Choi SH, Huh KB. ApoB/ApoA-I ratio is inde-
pendently associated with carotid atherosclerosis in type 2 dia-
betes mellitus with well-controlled LDL cholesterol levels. Ko-
rean J Intern Med 2018;33:138-47.
20.  Touboul PJ, Hennerici MG, Meairs S, Adams H, Amarenco P, 
Bornstein N, Csiba L, Desvarieux M, Ebrahim S, Hernandez 
Hernandez R, Jaff M, Kownator S, Naqvi T, Prati P, Rundek T, 
Sitzer M, Schminke U, Tardif JC, Taylor A, Vicaut E, Woo KS. 
Mannheim carotid intima-media thickness and plaque con-
sensus (2004-2006-2011). An update on behalf of the advisory 
board of the 3rd, 4th and 5th watching the risk symposia, at the 
13th, 15th and 20th European Stroke Conferences, Mannheim, 
Germany, 2004, Brussels, Belgium, 2006, and Hamburg, Ger-
many, 2011. Cerebrovasc Dis 2012;34:290-6.
21.  Park SW, Kim SK, Cho YW, Kim DJ, Song YD, Choi YJ, Huh 
BW, Choi SH, Jee SH, Cho MA, Lee EJ, Huh KB. Insulin resis-
tance and carotid atherosclerosis in patients with type 2 diabe-
tes. Atherosclerosis 2009;205:309-13.
22.  Walters DP, Gatling W, Mullee MA, Hill RD. The prevalence, 
detection, and epidemiological correlates of peripheral vascu-
lar disease: a comparison of diabetic and non-diabetic subjects 
in an English community. Diabet Med 1992;9:710-5.
23.  Hirsch AT, Criqui MH, Treat-Jacobson D, Regensteiner JG, 
Creager MA, Olin JW, Krook SH, Hunninghake DB, Comerota 
AJ, Walsh ME, McDermott MM, Hiatt WR. Peripheral arterial 
disease detection, awareness, and treatment in primary care. 
JAMA 2001;286:1317-24.
24.  Rhee SY, Guan H, Liu ZM, Cheng SW, Waspadji S, Palmes P, 
Tai TY, Suwanwalaikorn S, Kim YS; PAD-SEARCH Study 
Group. Multi-country study on the prevalence and clinical fea-
tures of peripheral arterial disease in Asian type 2 diabetes pa-
tients at high risk of atherosclerosis. Diabetes Res Clin Pract 
2007;76:82-92.
25.  Ghosh US, Datta S, Banerjee S. Asymptomatic peripheral arte-
rial disease in type 2 diabetes mellitus: prevalence patterns and 
risk factor associations. Int J Diabetes Dev Ctries 2011;31:229-
38.
26.  Weitz JI, Byrne J, Clagett GP, Farkouh ME, Porter JM, Sackett 
DL, Strandness DE Jr, Taylor LM. Diagnosis and treatment of 
chronic arterial insufficiency of the lower extremities: a critical 
review. Circulation 1996;94:3026-49.
27.  Antonopoulos S, Kokkoris S, Stasini F, Mylonopoulou M, Lep-
eniotis G, Mikros S, Korantzopoulos P, Giannoulis G. High 
prevalence of subclinical peripheral artery disease in Greek 
hospitalized patients. Eur J Intern Med 2005;16:187-91.
28.  Natsuaki C, Inoguchi T, Maeda Y, Yamada T, Sasaki S, Sonoda 
N, Shimabukuro M, Nawata H, Takayanagi R. Association of 
borderline ankle-brachial index with mortality and the inci-
dence of peripheral artery disease in diabetic patients. Athero-
sclerosis 2014;234:360-5.
29.  Kajikawa M, Maruhashi T, Iwamoto Y, Iwamoto A, Matsumoto 
T, Hidaka T, Kihara Y, Chayama K, Nakashima A, Goto C, 
Noma K, Higashi Y. Borderline ankle-brachial index value of 
0.91-0.99 is associated with endothelial dysfunction. Circ J 
2014;78:1740-5.
30.  Tanaka S, Kaneko H, Kano H, Matsuno S, Suzuki S, Takai H, 
Otsuka T, Uejima T, Oikawa Y, Nagashima K, Kirigaya H, Sag-
ara K, Yajima J, Sawada H, Aizawa T, Yamashita T. The predic-
tive value of the borderline ankle-brachial index for long-term 
clinical outcomes: an observational cohort study. Atheroscle-
rosis 2016;250:69-76.
31.  Ovbiagele B. Association of ankle-brachial index level with 
stroke. J Neurol Sci 2009;276:14-7.
32.  de Vries M, Ouwendijk R, Flobbe K, Nelemans PJ, Kessels AG, 
Schurink GH, van der Vliet JA, Heijstraten FM, Cuypers PW, 
Duijm LE, van Engelshoven JM, Hunink MG, de Haan MW. 
Peripheral arterial disease: clinical and cost comparisons be-
tween duplex US and contrast-enhanced MR angiography. A 
multicenter randomized trial. Radiology 2006;240:401-10.
33.  Collins R, Burch J, Cranny G, Aguiar-Ibanez R, Craig D, 
Wright K, Berry E, Gough M, Kleijnen J, Westwood M. Duplex 
ultrasonography, magnetic resonance angiography, and com-
puted tomography angiography for diagnosis and assessment 
of symptomatic, lower limb peripheral arterial disease: system-
atic review. BMJ 2007;334:1257.
Color Doppler ultrasonography and PAD
73Diabetes Metab J 2018;42:63-73http://e-dmj.org
34.  Bembi V, Singh S, Singh P, Aneja GK, Arya TV, Arora R. Preva-
lence of peripheral arterial disease in a cohort of diabetic pa-
tients. South Med J 2006;99:564-9.
35.  Lundberg C, Hansen T, Ahlstrom H, Lind L, Wikstrom J, Jo-
hansson L. The relationship between carotid intima-media 
thickness and global atherosclerosis. Clin Physiol Funct Imag-
ing 2014;34:457-62.
36.  Lorenz MW, Markus HS, Bots ML, Rosvall M, Sitzer M. Pre-
diction of clinical cardiovascular events with carotid intima-
media thickness: a systematic review and meta-analysis. Circu-
lation 2007;115:459-67.
37.  Pradeepa R, Chella S, Surendar J, Indulekha K, Anjana RM, 
Mohan V. Prevalence of peripheral vascular disease and its as-
sociation with carotid intima-media thickness and arterial 
stiffness in type 2 diabetes: the Chennai urban rural epidemiol-
ogy study (CURES 111). Diab Vasc Dis Res 2014;11:190-200.
38.  Bosevski M, Borozanov V, Tosev S, Peovska I, Meskovska-
Bongard S, Georgievska-Ismail L. Predictors for peripheral and 
carotid revascularization in a population-based cohort with 
type 2 diabetes. Angiology 2009;60:46-9.
